OncoGenex to Initiate Rainier Clinical Trial Evaluating OGX-427 with ABRAXANE plus Gemcitabine

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI ) today announced plans for the initiation of the Rainier™ trial, an investigator-sponsored, randomized, placebo-controlled Phase 2 trial evaluating OGX-427 in combination with ABRAXANE® (paclitaxel protein-bound particles for injectable suspension)(albumin-bound) and gemcitabine in patients with previously untreated metastatic pancreatic cancer. Rainier will randomize approximately